, 2020 Subject Management’ discussion and analysis for the fiscal year ended December 31, 2019 To President The Stock Exchange of Thailand Interpharma Public Company Limited ( “ the Company” ) would like
cost was 10.05 Million Baht or an increase of 7.18 Million Baht which is equivalent to an increase of 250.17 % from the previous year. For the period of six months of the fiscal year 2017, the Company's
year. For the period of nine months of the fiscal year 2017, the Company's financing cost was 42.48 Million Baht, increased by 32.67 Million Baht, or up by 333.03% from the previous year. The result was
No: AH 03052021 May 17, 2021 Subject: Management Discussion & Analysis (MD&A) for the financial statements of the 1st quarter of fiscal year 2021 ended as of March 31, 2021 To: The President The Stock
No: AH 02112021 November 12, 2021 Subject: Management Discussion & Analysis (MD&A) for the financial statements of the 3rd quarter of fiscal year 2021 ended as of September 30, 2021 To: The President
No: AH 03052022 May 17, 2022 Subject: Management Discussion & Analysis (MD&A) for the Financial Statements of the 1st Quarter of Fiscal Year 2022 Ended as of March 31, 2022 To: The President The Stock
No: AH 02052023 May 11th, 2023 Subject: Management Discussion & Analysis (MD&A) for the Financial Statements of the 1st Quarter of Fiscal Year 2023 Ended as of March 31, 2023 To: The President The
market has remained competitive since end-2017. Overall, operators more carefully spent on marketing activities. Postpaid segment continued to be the main focus where handset subsidies and network quality
2% YoY, going at the same direction of the slowdown in food and beverage segment. Proportion of each market segment and growth of domestic RTD fruit juice market is as shown in figure 2 (Source